- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
GenomeFIRST Awarded $400K Grant to Bring Genomic Information into Patients' Care Plans
Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.
Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.
According to the press release:
The GenomeFIRST Medicine program takes a comprehensive approach to care that includes genomic screening, interpretation and managing results — essentially changing health care by expanding providers’ ability to care for their patients before a problem arises. With support from the Robert Wood Johnson Foundation, Geisinger will pilot a scalable model for integrating genomic results into the everyday care of 300 Geisinger patients. The project will focus on the three most common genetic conditions in Geisinger’s GenomeFIRST program: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch Syndrome, and Familial Hypercholesterolemia.
Dr. Michael Murray, director of clinical genomics, Geisinger Genomic Medicine Institute commented:
As we enter the era of precision health, we will increasingly use genetic information to identify health risk and then use preventive strategies to avoid disease. This program is building the infrastructure to do that. At Geisinger, we strongly believe that genome sequencing will become more and more integrated into routine care, and that GenomeFIRST Medicine will drive medicine toward early diagnoses and disease prevention for many of our patients.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â